[5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid is a **synthetic compound** belonging to the family of **nonsteroidal anti-inflammatory drugs (NSAIDs)**.
It's important to understand that this is **not a commercially available drug**. It's likely a research compound being investigated for its potential pharmacological properties. Here's why it's interesting for research:
**1. Chemical Structure and Potential for Activity:**
* **Indene ring system:** The indene ring structure is a common motif in NSAIDs. It's known to interact with the enzyme **cyclooxygenase (COX)**, which plays a crucial role in the production of prostaglandins, chemicals involved in inflammation and pain.
* **Benzylidene group:** This group, attached to the indene ring, can influence how the compound binds to COX and potentially enhances its activity.
* **Fluorine and isopropyl groups:** These substituents can affect the drug's properties like:
* **Solubility:** How well it dissolves in the body
* **Metabolism:** How it's broken down in the body
* **Potency:** How effective it is at its intended target
**2. Research Applications:**
* **Anti-inflammatory activity:** Research on this compound likely focuses on understanding its potential to reduce inflammation and pain in various models.
* **Selective COX-2 inhibition:** Some NSAIDs are known to inhibit COX-2 selectively, which can minimize gastrointestinal side effects. Research might explore if this compound exhibits this selectivity.
* **Novel drug development:** Understanding this compound's activity can lead to the development of new NSAIDs with improved efficacy or fewer side effects.
**Important Considerations:**
* **Pre-clinical studies:** Research on [5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid is likely in early stages, focusing on pre-clinical studies (in vitro and animal models).
* **Safety and efficacy:** Before any drug can be used in humans, extensive research is needed to determine its safety and efficacy.
**In summary:** [5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid is a synthetic compound with the potential for anti-inflammatory activity due to its NSAID-like structure. Research on this compound aims to explore its pharmacological properties and potentially contribute to the development of new therapeutic options.
K-80003: sulindac derivative that inhibits activation of phosphoinositide 3-kinase (PI3K) by retinoid X receptor alpha (RXRalpha) in tumor cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
[5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid : A sulindac-based non-steroidal anti-inflammatory drug. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 46224594 |
| CHEMBL ID | 2337793 |
| CHEBI ID | 59660 |
| SCHEMBL ID | 2593408 |
| Synonym |
|---|
| CHEBI:59660 , |
| k-80003 |
| [5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid |
| [(1z)-5-fluoro-1-(4-isopropylbenzylidene)-2-methyl-1h-inden-3-yl]acetic acid |
| bdbm50430574 |
| CHEMBL2337793 , |
| SCHEMBL2593408 |
| 4s7931g4pp , |
| 1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(1-methylethyl)phenyl)methylene)-, (1z)- |
| 1292821-90-9 |
| tx-803 |
| unii-4s7931g4pp |
| 7a4 , |
| [(1z)-5-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1h-inden-3-yl]acetic acid |
| Q27126837 |
| HY-U00458 |
| CS-0039348 |
| gtpl10347 |
| 2-[(3z)-6-fluoro-2-methyl-3-[(4-propan-2-ylphenyl)methylidene]inden-1-yl]acetic acid |
| MS-25102 |
| AKOS040733512 |
| Role | Description |
|---|---|
| non-steroidal anti-inflammatory drug | An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | IC50 (µMol) | 2.4000 | 0.0060 | 0.4450 | 2.4000 | AID734227 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | Kd | 2.3800 | 0.0004 | 0.5838 | 8.8000 | AID1624017 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 (µMol) | 50.0000 | 0.0000 | 0.9922 | 10.0000 | AID1767809 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Kd | 100.0000 | 0.0012 | 0.9531 | 4.9800 | AID1767811 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID734236 | Antagonist activity at RXRalpha (unknown origin) expressed in HCT116 cells assessed as inhibition of 9-cis-RA-induced galactosidase activity after 12 hrs by gal4 reporter gene assay | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. |
| AID1767810 | Partial agonist activity at GAL4 DBD-fused PPARgamma LBD (unknown origin) expressed in pG5 luc and pBIND transfected HEK293T cells assessed as maximum fold induction incubated for 12 hrs by fluorescence based luciferase assay relative to control | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy. |
| AID734231 | Inhibition of RXRalpha in human HCT116 cells assessed as inhibition of TNFalpha-induced Akt phosphorylation | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. |
| AID734227 | Displacement of [3H]-9-cis-RA from RXRalpha (unknown origin) by liquid scintillation counting | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. |
| AID734232 | Inhibition of RXRalpha in human A549 cells assessed as inhibition of TNFalpha-induced Akt phosphorylation at 30 uM incubated for 1 hr prior to TNFalpha-induction measured after 30 mins by Western blot analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. |
| AID734230 | Inhibition of RXRalpha in human HepG2 cells assessed as inhibition of TNFalpha-induced Akt phosphorylation | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. |
| AID1624017 | Inhibition of 9-cis-retinoic acid competition binding to RXRalpha LBD (unknown origin) by fluorescence quenching method | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Design, synthesis and biological evaluation of tetrazole-containing RXRα ligands as anticancer agents. |
| AID734228 | Induction of apoptosis in human HCT116 cells assessed as increase in TNFalpha-induced PARP cleavage at 40 uM after 4 hrs by Western blot analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. |
| AID1767811 | Binding affinity to GAL4-DBD-fused PPARgamma ligand binding domain (unknown origin) expressed in HEK293T cells by spectra-fluorophotometry analysis | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy. |
| AID734233 | Induction of apoptosis in human ZR75-1 cells assessed as PARP cleavage at 30 uM after 6 hrs by Western blot analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. |
| AID1767809 | Partial agonist activity at GAL4 DBD-fused PPARgamma LBD (unknown origin) expressed in pG5 luc and pBIND transfected HEK293T cells assessed as transcriptional activation incubated for 12 hrs by fluorescence based luciferase assay | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||